HCPCS A2010
APIS® by SweetBio®
Known ingredients, proven independently, powerful together.
Made with an intentional synthesis of trusted materials, APIS® is designed to cover and protect wounds, absorb exudate, and create a moist wound environment. Published in multiple peer-reviewed publications demonstrating 2x faster wound closure across both chronic and acute wounds.
Backed by Evidence
Collagen + Mānuka Honey + Hydroxyapatite Like Never Before
Uniquely engineered for use throughout the full healing cascade — from early bacteria and inflammation to late-stage proliferation and remodeling.
4–8 wk
Wound closure
Reported closure across chronic and acute wounds in peer-reviewed studies.
99.99%
Bacteria reduction
In vitro reduction within 24 hours from the Mānuka honey component.
Lower
Reported pain
Patients reported lower pain versus standard secondary intention healing.
Multi
Growth factor release
Promotes inflammation reduction and growth factor secretion throughout healing.
Next-level convenience
Supplied as an all-in-one sheet, APIS® is ready to apply in minutes, can be trimmed or folded, and naturally conforms to the wound bed.
Reimbursement-ready
Established HCPCS code A2010 with a clear billing pathway, positioned for stability in the evolving reimbursement landscape.
Our MX® Technology
Designed to Address the Demands of Healing
We meticulously deconstructed natural elements to reimagine and rebuild a new biomaterial, MX®, with a unique chemical fingerprint that transcends the sum of its parts.
Collagen Derivative
A natural, porcine-derived extracellular matrix protein beneficial for cell migration, adhesion, and proliferation.
Mānuka Honey
100% UMF-certified New Zealand Mānuka honey known for antibacterial and anti-inflammatory effects.
Hydroxyapatite
A naturally occurring mineral known to bind proteins and promote healing via angiogenesis.
APIS® In Action
Diabetic Foot Ulcer (Heel)
Near complete closure at week 4 with complete closure at week 5 — after 12 months of failed treatment with other wound care products.
Patient
60-year-old male
Diabetes, hypertension, PVD, neuropathy
Prior Treatment
12 months
Various products, no resolution
With APIS®
5 weeks to closure
4 applications across 5 visits
“Traditionally, my wounds have taken 14–18 weeks to close. After 5 weeks of APIS®, my wound closed. I can easily take a shower again.”
Indications
Under the supervision of a healthcare professional, APIS® is indicated for use in the management of a wide range of wound types.
Available Sizes
APIS® is supplied in an all-in-one sheet that can be trimmed or folded to fit the wound bed.
| Size | SKU | Coverage Area |
|---|---|---|
| 1.6 × 1.6 cm | APIS-16x16-2 | 2.56 cm² |
| 2.5 × 2.5 cm | APIS-25x25-2 | 6.25 cm² |
| 5.0 × 5.0 cm | APIS-50x50-2 | 25 cm² |
Coming soon in 6.0 × 8.0 cm
Clinical Evidence
APIS® is supported by peer-reviewed clinical research demonstrating efficacy across the full healing cascade.
Novel bioengineered collagen + Manuka honey + hydroxyapatite sheet for the treatment of lower extremity chronic wounds in an urban hospital wound care setting
Rodriguez et al. (2023)
Preliminary clinical evaluation of a novel bioengineered wound product: A focus on the management of lower extremity ulcers
Rodriguez et al. (2020)
Use of a Novel Biomaterial to Enhance Secondary Intention Healing
McMurray et al. (2021)
Novel Biomaterial Containing Gelatin, Manuka Honey, and Hydroxyapatite Enhanced Secondary Intention Healing Versus Standard Secondary Intention Healing in Mohs Surgical Defects — A Randomized Controlled Trial: Pilot Study
Arnaud et al. (2023)
A novel bioengineered wound product with in vitro capabilities to reduce bacteria
Williams et al. (2021)
Microenvironment influence of a novel bioengineered wound product APIS®: An in vitro analysis of inflammatory marker and growth factor secretion
Rodriguez et al. (2021)
A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products
Rodriguez et al. (2022)
* Based on clinical and in vitro data; claims have not been cleared by the FDA. Faster wound closure reported in slower healing and chronic wounds compared to standard of care.
Heal Faster. Improve Outcomes.
Partner with DermaLynx to bring APIS® and our complete portfolio of advanced wound care solutions to your practice.